Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Instagram Outage Disrupts Thousands of U.S. Users 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
HEIDELBERG, Germany, May 31, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 8:30 a.m. (ET) in New York City.
To access a simultaneous webcast of Dr. Hoess' presentation online, log on to http://wsw.com/webcast/jeff97/afmd or go to the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available from Affimed's website for 30 days following the conference. Dr. Hoess' presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of Affimed's website at http://www.affimed.com/events.php.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
